The Single Use bioprocessing Market has a market size of USD 46.56 billion and it is estimated to grow at 20.8% CAGR during the period from 2023-2032. As the Single-Use Bioprocessing Market proceeds in constant growth, a range of factors that present an increasing demand for single-use technologies in biopharmaceutical manufacturing are responsible for the market expansion. The key reason is of course the necessity of flexibility and efficiency in bioprocessing operations. The advantage of single-use bioprocessing systems include disposable bags, bioreactors, and tubing sets that provide a flexible scalable manufacturing approach that can facilitate faster turnaround times, lower contamination risks, and higher operation efficiency. This adaptability plays a significant role in biopharmaceutical production in the face of dynamic scenarios of scale of production and processes modifications.
Technologies and innovations are centerpieces of the development of Single-Use Bioprocessing Market. There is a plethora of new materials, more efficient designs, and advanced functions that make single-use bioprocessing equipment a preferred choice of many. Bioprocessing manufacturers are into developing new single-use technologies that in turn will solve the specific challenges of biomanufacturing such as scalability, robustness and compatibility with other processes.
Cost-effectiveness of single-use bioprocessing systems also contributes to the market factor. Bioprocessing technology relies on conventional stainless-steel devices that require a substantial amount of money to be invested upfront, whilst also facing long setup time as well as complex cleaning and validation procedures. One of the advantages of using single-use platforms is that the systems do not require extensive cleaning and validation, thereby lowering downtime between batches and operating costs. The overall cost effectiveness of simpler technologies makes them a very attractive choice not only for well-established pharmaceutical companies but also for emerging biotech startups.
The other market aspect relates to the prevailing trend of biopharmaceutical outsourcing and contract manufacturing arrangements. Due to the increasing number of CMOs using single-use bioprocessing technologies, they can manufacture cost-effective and flexible processing solutions. The implementation of single-use bioprocess technologies enables CMOs to adjust quickly to fluctuating customer requirements, to utilize resources appropriately, and to set more cost-effective pricing for the production of biopharmaceuticals.
The regulatory support and industry standards are the key factors that should be taken into account within the Single-Use Bioprocessing Market. The regulatory authorities acknowledge the benefits of the single-use technologies, granted that they satisfy all the specific mandates. The alignment of industry standards and regulatory frameworks maintain the reliability and consistency of the single-use bioprocessing systems, and due to this manufacturers feel safe to adopt such instruments for the production of therapeutic biologics.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2022 | USD 8.5 Billion |
Market Size Value In 2023 | USD 10.27 Billion |
Growth Rate | 20.80% (2023-2032) |
Single Use Bioprocessing Market Size was valued at USD 8.5 Billion in 2022. The Single Use Bioprocessing market industry is projected to grow from USD 10.27 Billion in 2023 to USD 46.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.80% during the forecast period (2024 - 2032). The increasing need for biopharmaceuticals and increased usage of one-time-use gadgets are the key market drivers boosting the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for single use bioprocessing is being driven by the fact that strategically acquiring single-use technology can boost biopharmaceutical industry acceptance. Simplifying processes, cutting down on waste, and enhancing quality control are all made easier and more affordable with single-use technologies. In order to get a competitive edge in a crowded market, businesses should consider strategically obtaining high-quality single-use technologies. Increasing process visibility and control through the deliberate acquisition of single-use technology can lead to more openness and conformity with industry norms. Companies that want to save money, work more efficiently, and gain an edge in the market often make deliberate purchases of single-use technologies. In addition, businesses are forming alliances to enter regional markets for one-time bioprocessing applications.
Additionally, new advances in technology have been crucial in the rollout of novel single-use bioprocess consumables around the world. Market participants in the field of single-use bioprocessing have released new solutions that make the practice far more secure, user-friendly, and productive. Companies have been able to increase their market share by adapting to these trends and needs. The increasing production and usage of biopharmaceuticals and bio-similar are the primary forces propelling the single-use bioprocessing industry. When it comes to manufacturing biopharmaceuticals, bio-therapeutics, vaccines, monoclonal antibodies, and bio-similar, single-use bioprocessing offers a highly advantageous platform.
However, it is expected that the high price of single use bioprocessing solutions will slow the expansion of the market. On the other hand, Due to potential effects on product quality and patient health, concerns about extractable and leachables originating from the components of single-use bioprocessing systems may impede market expansion.
For instance, Lonza has established a strategic partnership with Torchlight, an industry leader in enzymatic DNA manufacturing, to facilitate the development of revolutionary new approaches to genetic therapy. This partnership will allow Lonza to provide a more complete product offering to customers developing mRNA vaccines and treatments by incorporating an additional, converted source of DNA. As a result, it is expected that throughout the projection period, demand for single use bioprocessing is due to the increasing technological advancement. Thus driving the single use bioprocessing market revenue.
The Single Use Bioprocessing Market segmentation, based on product, includes filtration assemblies, disposable bioreactors, disposable mixers, media bags & containers, and others. The media bags & containers segment dominated the market because the usage of media bags and containers in the biopharmaceutical industry reduces operational expenses, waste emissions, and capital expenditures. The disposable media bags and containers are also resistant to heat and cold. As a result, the sector's recent expansion has been bolstered by the widespread use of media bags and containers in the biopharmaceutical sector.
Figure 1: Single Use Bioprocessing Market, by Product, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Single Use Bioprocessing Market segmentation, based on application, includes filtration, purification, cell culture, and others. In 2022, the filtration segment sector held the highest market share globally, accounting for over 48.1%% of the total revenue because of the increased use of disposable bioprocessing equipment for filtration because of the system's high efficiency, even at the industrial scale. Its applications include bio-burden reduction, biomolecule polishing, and ultrafiltration.
The Single Use Bioprocessing Market segmentation, based on end users, includes biopharmaceutical manufacturers, clinical & academic research institutes, and others. In 2022, the worldwide single use bioprocessing market share was dominated by the biopharmaceutical manufacturers category because of the cost savings, increased productivity, and increased reliability offered by single-use bioprocessing systems, more than 80% of biopharmaceutical manufacturing facilities have made the switch.
The Single Use Bioprocessing Market segmentation, based on workflow, includes upstream, fermentation, and downstream. The upstream segment dominated the market because of unit operations upstream in the bioprocessing cycle, such as cell culture, protein expression, and harvest, are the primary focus of single-use technologies. Improvements to this workflow over the recent year have helped biopharmaceutical firms standardize procedures, boost output, and cut expenses. Advances in upstream single-use bioprocessing have given biopharmaceutical firms a more productive and less expensive process.
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American single use bioprocessing market area will dominate this market because of several factors, including large-scale manufacturing units, rising disposable adoption, increasing healthcare spending, and a highly established healthcare infrastructure. The region's single-use bioprocessing market is also booming due to the prevalence of contract manufacturers and the widespread adoption of disposables within the industry.
Further, the major countries studied in the market report are The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: SINGLE USE BIOPROCESSING MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe’s single use bioprocessing market accounts for the second-largest market share because of rising investments in R&D and production, widespread adoption of disposable products, rising healthcare costs, and a mature healthcare infrastructure. Further, the German single use bioprocessing market held the largest market share, and the UK single use bioprocessing market was the fastest-growing market in the European region.
The Asia-Pacific single use bioprocessing Market is predicted to grow at the highest CAGR from 2023 to 2032. This is because of the booming biopharmaceutical industry across the globe. Additionally, Asia Pacific is to start emerging as the pharmaceutical industry's production hub as a result of increased investments by biotechnology and pharmaceutical businesses and the rapid rise of contract manufacturers. Therefore, the area may play a crucial role in the development of the single-use bioprocessing market in the years to come. Moreover, China’s single use bioprocessing market held the largest market share, and the Indian single use bioprocessing market was the fastest-growing market in the Asia-Pacific region.
Single Use Bioprocessing Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the single use bioprocessing market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the single use bioprocessing industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global single use bioprocessing industry to benefit clients and increase the market sector. In recent years, the single use bioprocessing industry has offered some of the most significant advantages to medicine. Major players in the single use bioprocessing market, including Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Pall Corporation, Corning Incorporated, Eppendorf AG, General Electric Company (GE Healthcare), Lonza, Rentschler Biopharma SE, JM BioConnect, Meissner Filtration Products, Inc., Infors AG, Boehringer Ingelheim GmbH, Entegris, Inc., and PBS Biotech Inc.
Akron BioProducts provides the premier cell and gene therapy products and services available today. In order to help advanced therapy developers speed up the process of bringing new medicines to market, Akron has earned ISO 13485 certification by adhering to cGMP criteria and international standards. In April 2022, Akron BioProducts, a leading manufacturer of cGMP-compliant materials and technology for cell and gene therapy manufacturing, released a new product line called Closed System Solutions, which is meant to seal off essential stages of production hermetically.
Merck is a well-known scientific and technological business that works in the fields of electronics, healthcare, and life sciences. By developing more happy and sustainable lifestyle options, more than 64,000 professionals strive to impact millions of people's lives every day positively. The company is widely recognized for its ability to create and manufacture drugs more quickly, find novel approaches to treating the most difficult ailments, and empower gadgets with intelligence. In June 2023, Merck announced an expansion of its facility in Lenexa, Kansas, making it the company's largest dry powder cell culture media facility and Center of Excellence in North America. Expand capabilities with new lab space and 9,100 sq m of additional manufacturing space.
Key Companies in the Single Use Bioprocessing market include
Single Use Bioprocessing Industry Developments
January 2023: Boehringer Ingelheim has opened its state-of-the-art Biologicals Development Center in Biberach a der Riß, Germany. The company's commitment to Germany and Europe as a center of R&D is on display in the form of a brand-new, cutting-edge facility. German pharmaceuticals manufacturer Boehringer Ingelheim has spent 350 million Euros on research and development expansion and biopharmaceutical capabilities.
March 2022: SPARTA Biodiscovery and the SPARTA analytical platform are working together to speed up the development, manufacturing, and quality control of nanoparticles for biopharmaceutical treatments.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)